Anti-inflammatory effects of inhaled beclomethasone dipropionate in nonatopic asthmatics.
The effects of inhaled beclomethasone dipropionate (BDP) on asthma symptoms and infiltration of the bronchial mucosa by inflammatory cells were investigated in an open study of 10 patients with mild-to-moderate nonatopic bronchial asthma. Asthma scores were recorded in an asthma diary. Peak expiratory flow (PEF), PEF diurnal variation (PEF%), forced expiratory volume in one second (FEV1%), methacholine airway hypersensitivity (minimum dose of methacholine) (Dmin) were measured. Biopsy of the bronchial mucosa was performed before and after 8 weeks of treatment with BDP (400 micrograms.day-1). The following inflammatory cells were immunostained: eosinophils with anti-EG2; mast cells with AA1; neutrophils with NP57; T-lymphocytes with anti-CD3, CD4, and CD8; and activated T-lymphocytes with anti-CD25. There was a significant improvement in the asthma symptom score, PEF%, FEV1%, and Dmin after BDP therapy and the number of EG2-, AA1-, CD3-, CD4-, and CD25-positive cells decreased significantly. We conclude that inhaled beclomethasone dipropionate inhibited inflammatory cell infiltration of airway tissue and that associated with this there was an improvement of symptoms in this open study of inhaled beclomethasone dipropionate in a group of nonatopic asthmatic subjects.
Hoshino
M
M
Second Dept of Internal Medicine, Toho University School of Medicine, Tokyo, Japan.
Nakamura
Y
Y
D000328:Adult; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology; D001507:Beclomethasone / Q000627:therapeutic use*; D001706:Biopsy; D001980:Bronchi / Q000276:immunology / Q000473:pathology; D001985:Bronchial Provocation Tests; D002452:Cell Count; D004804:Eosinophils / Q000187:drug effects; D005260:Female; D006801:Humans; D018655:Lymphocyte Count; D008297:Male; D008407:Mast Cells / Q000187:drug effects; D008875:Middle Aged; D009092:Mucous Membrane / Q000276:immunology; D009330:Nebulizers and Vaporizers; D009504:Neutrophils / Q000187:drug effects; D016176:T-Lymphocyte Subsets / Q000187:drug effects
D018927:Anti-Asthmatic Agents; D001507:Beclomethasone